Anavex Life Sciences Corp (AVXL)

[crescentmotor]

ABCLEAR 2 and 3 are post-hoc -- adds absolutely zero value to the MAA.

Nothing post-hoc about the 48 week trial results for the ABCLEAR1 patients, whose cognitive scores improved by 49.8% over placebo.

where dropouts for treated patients far outpaced the placebo arm

Subsequent changes to the dose titration resulted in dropouts equal to the placebo group.

The OLE and ADNI comparison adds very little value to the MAA

However, it isn't rocket science to project the decline of AD patients at the three and four-year mark since declines have been well documented in thousands of those patients. That's where Blarcamesine shows very convincing efficacy results both in cognition and functional improvement that should not be ignored solely because it is outside of the 48 week trial window. Given the obvious safety of Blarcamesine, common sense argues for approval with requirements for further confirmatory data.

Hopefully common sense will prevail over the anal views of those married to ancient and rigid concepts no longer valid in modern science.